AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get moving
Target
Upside 114%
Price (€) 4.53
Market Cap (€M) 164
Perf. 1W: 3.08%
Perf. 1M: 30.4%
Perf. 3M: 16.0%
Perf Ytd: 37.3%
10 day relative perf. to stoxx600: 7.09%
20 day relative perf. to stoxx600: 18.6%
Financing issue 17/12/2021

New financing

Crossject has announced the issuance of convertible bonds.

It also grants free subscription rights to existing shareholders.

The financing of FY22 is thus secured and gives the group time to reach the market.

We will fine-tune our model and integrate this issuance.


Fact

Crossject has just announced the issuance of convertible bonds and the free granting of subscription rights to its shareholders.


Analysis

In an unsurprising move, the group announced it has issued €7.5m in convertible bonds (no coupon, issued at 92% of its nominal value and maturing on 31 December 2024), including €1.5m by Gemmes Venture, its main shareholder, and other qualified investors. The conversion price will be the minimum between €3.30 and 92% of a weighted average share price during a period before the conversion. The group also announced that existing shareholders (as at 31 December 2021) will be granted free subscription rights, every 20 rights enabling them to buy a share at a price of €3 between 12 January and 30 June 2022. This could lead to the issuance of 1.3m shares and a strengthening of shareholders’ funds by €3.9m.

Altogether (i.e. including convertible bonds) the group could raise as much as €11.5m during FY22 (without taking into account potential licensing revenues or subsidies) which should rather easily fill its needs for the coming year.

Looking beyond FY22, the visibility is less clear since it is still too early to assess the potential cash inflows that could benefit the company during the coming year. However, we take the news as rather good since it secures FY22 and shows once again the confidence of its main shareholders.


Impact

We will adjust our numbers to take into account the convertible issuance.


Updates

26 Sep 22 EPS change
Minor changes after H1 22

23 Sep 22 Earnings/sales releases
A rather reassuring H1 22

29 Mar 22 Earnings/sales releases
FY21: not very meaningful, as expected

17 Dec 21 Financing issue
New financing

24 Sep 21 Earnings/sales releases
H1 21: unsurprising (as usual)

.